Jefferies Financial Group Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 price objective on the stock.

Separately, Wedbush initiated coverage on shares of Oruka Therapeutics in a research note on Wednesday, September 4th. They set an outperform rating and a $40.00 target price on the stock.

Oruka Therapeutics Trading Up 4.1 %

Shares of Oruka Therapeutics stock opened at $25.90 on Friday. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.